The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The container ship Sky Light caused chaos while docking at a port in Constanța, Romania, on September 19. While attempting to ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...

Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli ...

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...

The company has been doing incredibly well, and revenue as well as profits have skyrocketed in recent quarters. Shares of ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.

Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.